{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:33:34Z","timestamp":1762432414554,"version":"3.40.5"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,26]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Low-dose methotrexate has a relatively good safety profile. However, in cases where patients with multiple risk factors, a delayed excretion has been observed, resulting in the occurrence of severe adverse reactions. It is necessary to supervise and intervene throughout the entire process of treating patients with multiple risk factors for methotrexate, and to strengthen the rational application of methotrexate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnoses:<\/jats:title>\n            <jats:p>A 66-year-old male patient was admitted to our hospital with rheumatoid arthritis and underlying conditions such as chronic obstructive pulmonary disease (COPD). This patient received treatment with low-dose MTX (10\u2009mg\/week) and experienced adverse reactions including anemia. He was diagnosed with methotrexate-induced bone marrow suppression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>The therapeutic drug monitoring revealed that the serum drug concentration of methotrexate was at a critical level and the patient was rescue with calcium folinate and other adjuvant therapy such as transfusions of red blood cells, plasma, platelets, oral Yixuesheng tablets and Leucogen tablets. We conducted a 1-month follow-up, and there was no recurrence of bone marrow suppression and anemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>To ensure rational administration of methotrexate, it is important to fully evaluate the clinical manifestations and physical condition of patients and regularly detecting the serum drug concentration of methotrexate when patients with multiple risk factors, Otherwise, even low-dose methotrexate administration may cause delayed excretion, resulting in severe adverse reactions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037070","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T03:01:19Z","timestamp":1706756479000},"page":"e37070","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Delayed low-dose methotrexate excretion in a rheumatoid arthritis patient: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-4900","authenticated-orcid":false,"given":"Qingzi","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan central hospital, Xiangtan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan central hospital, Xiangtan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan central hospital, Xiangtan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan central hospital, Xiangtan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan central hospital, Xiangtan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis.","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R3-20250503","first-page":"225","article-title":"Methotrexate: implications of pharmacogenetics in the treatment of patients with rheumatoid arthritis.","volume":"1","author":"Torres","year":"2022","journal-title":"ARP Rheumatol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11655-009-0063-3","article-title":"Clinical observation on the treatment of male neoplastic anemia with Yixuesheng capsule combined with recombination human erythropoietin.","volume":"15","author":"Cheng","year":"2009","journal-title":"Chin J Integr Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-018-1544-9","article-title":"Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.","volume":"20","author":"Bluett","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review.","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1200\/JCO.2015.62.6341","article-title":"Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an ancillary study of CALGB\/CTSU 49907.","volume":"34","author":"Lichtman","year":"2016","journal-title":"J Clin Oncol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"bcr2014207142","DOI":"10.1136\/bcr-2014-207142","article-title":"Ascites and other incidental findings revealing undiagnosed systemic rheumatoid arthritis.","volume":"2015","author":"Szeto","year":"2015","journal-title":"BMJ Case Rep"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/DHPS.S350194","article-title":"Pancytopenia due to possible drug-drug interactions between low-dose methotrexate and proton pump inhibitors.","volume":"14","author":"Tao","year":"2022","journal-title":"Drug Healthc Patient Saf"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1994.tb05713.x","article-title":"Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis.","volume":"37","author":"Tracy","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.annder.2018.05.001","article-title":"Drug interactions between methotrexate and antibiotics.","volume":"145","author":"Schmutz","year":"2018","journal-title":"Ann Dermatol Venereol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/pgs-2019-0186","article-title":"MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis.","volume":"21","author":"Sundbaum","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"300060519879588","DOI":"10.1177\/0300060519879588","article-title":"Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in chinese han patients with rheumatoid arthritis.","volume":"48","author":"Wang","year":"2020","journal-title":"J Int Med Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:08:20Z","timestamp":1746317300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037070","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}